Digital Twinning, and how EdgeTI (CTRL.V) is a serious story you’ve never heard of
Bionxt Solutions (BNXT.C): Seeking to confirm national-level cancer drug patent
Why Prospera Energy (PEI.V) might be a transformational investment opportunity in Canadian oil & gas
Sparc AI (SPAI.C) completes development of drone advanced target acquisition system
Plurilock (PLUR.V) lands $19 million deal, largest in their history
Rex Resources (OWN.V) continues gearing up with BC gold property
Today, Jody sits down once again with Ben Lightburn, CEO, director and co-founder of Filament Health (FH.NEO). Ben catches us up on the progress the medical psychedelics company has made since the start of the year including FDA approval of a Phase II clinical trial to investigate the effects of Filament’s lead drug candidate in treating patients suffering from major depressive disorder.
Enjoy!
Filament Health (FH.NEO) – Investor Roundtable Video #7